The Role of the HER-2/neu Oncogene in Gynecologic Cancers

Abstract

Objective: The HER-2/neu proto-oncogene (also known as c-erbB2, neu, and HER2) encodes a 185-kDa transmembrane glycoprotein with intrinsic tyrosine kinase activity that resembles the receptor for epidermal growth factor. Aberrant HER-2/neu protein overexpression occurs in human gynecologic adenocarcinomas, including those of the ovary, endometrium, breast, fallopian tube, and cervix, and is secondary to gene amplification and/or overexpression of the p185^HER2 protein.

Methods: A Medline literature search revealed numerous studies on HER-2/neu and tumor biology, cancer prognosis, and therapeutic targeting. We present a review of the literature pertinent to gynecologic malignancies.

Results: Overexpression of HER-2/neu was found to be a poor prognostic factor for survival from advanced-stage ovarian cancer, node-positive breast cancer, and endometrial cancer. Although a specific ligand has not been definitvely identified, HER-2/neu may have unusually complex activation pathways because it can from both homodimeric and heterodimeric associations with other related receptor proteins. Preliminary findings usggest that serum HER-2/neu levels may be used as a tumor marker in a subset of patients with tumors that overexpress the HER-2/neu receptor. Receptor-targeted therapeutics currently being studied include the use of receptor antibodies, liposomally delivered antisense DNA, antigen-activated cytotoxic lymphocytes, and adenovirus-mediated E1A delivery to overexpressing tumor cells.

Conclusion: HER-2/neu appears to play an important role in the biologic behavior of overian, endometrial, adn breast cancers and holds potential as a target for oncogene-directed therapies.

Keywords

HER-2/neu gynecologic cancer tumor marker gene-targeted therapy

Get full access to this article

View all access options for this article.

References

1. Padhy LC , Shih C , Cowing D , Finkelstein R . Weinberg RA, Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982;28:865-871.

2. Popescu NC , King CR , Kraus MH . Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4:362-366.

3. Bargman CI , Hung MC , Weinberg RA . The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-230.

4. Borg A , Tandon AK , Sigurdsson H , et al. HER-2/neu amplification predicts poor survival in node-negative breast cancer. Cancer Res 1990;50:433-437.

5. Tsuda H , Hirohashi S , Shimosato Y , et al. Immunohistochemical study on overexpression of c-cerbB-2 protein in human breast cancer: Its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990;81:327-332.

6. Berchuck A , Kamel A , Whitaker R , et al. Overexpression of HER-2neu is associated with poor survival in advanced epithelial overian cancer. Cancer Res 1990;50:4087-4091.

7. Slamon DJ , Godolphin W , Jones LA , et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712.

8. Hetzel DJ , Wilson TO , Keeney GL , Roche PC , Cha SS , Podratz KC , HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-185.

9. Rosen PP , Lesser ML , Arroyo CD , Cranor M , Borgen P , Norton L . Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative breast carcinoma. Cancer 1995;75:1320-1326.

10.

10. Higashiyama S , Abraham JA , Miller JF , Klagsburn M . A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-939.

11.

11. Burgess TL , Ross SL , Qian, YX , Brankow D , Hu S . Biosynthetic processing of neu differentiation factor. Glycosylation trafficking, and regulated cleavage from the cell surface. J Biol Chem 1995;270:19188-19196.

12.

12. Wada T , Qian XL , Greene MI . Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function. CEll 1990;61:1337-1347.

13.

13. Yarden Y . Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci U S A 1990;87:2569-2573.

14.

14. Samanta A , LeVea CM , Dougall WC , Quan X , Greene MI . Ligand and p185c-neu denstiy govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A 1994;91:1711-1715.

15.

15. Chazin VR , Kaleko M , Miller AD , Slamon DJ . Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859-1866.

16.

16. Scott GK , Robles R , Park JW , et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247-2257.

17.

17. Bacus SS , Huberman E , Chin K , et al. A ligand for the erbB-2 oncogenic product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992;3:401-411.

18.

18. Lin YJ , Clinton GM . A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 1991;6:639-643.

19.

19. Bosher JM , Williams T , Hurst HC . The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci U S A 1995;92:744-747.

20.

20. Brock ML , Shapiro DJ . Estrogen stabilizes vitellogenin mRNA against cytoplasmic degredation. Cell 1983;34:207-214.

21.

21. Karlan BY , Jones J , Slamon DJ , Lagasse LD . Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol 1994;53:70-77.

22.

22. Pietras RJ , Arboleda J , Reese DM , et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-2446.

23.

23. Rubin SC , Finstad CL , Wong GY , Almadrones L , Plante M , Lloyd KO . Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 1993;168:162-169.

24.

24. Haldane JS , Hird V , Hughes CM , Gullick WJ . c-erbB-2 oncogene expression in ovarian cancer. J. Pathol 1990;162:231-237.

25.

25. Wilkinson N , Todd N , Buckley CH , Gusterson BA , Fox H . An immunohistochemcial study of the incidence and significance of c-erbB-2 oncoprotein overexpression in ovarian neoplasia. Int J Gynecol Cancer 1991;1:258-259.

26.

26. Rubin SC , Finstad CL , Federici MG , Scheiner L , Lloyd KO , Hoskins WJ . Revalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;73:1456-1459.

27.

27. Buller RE , Anderson B , Connor JP , Robinson R . Familial overian cancer. Gynecol Oncol 1993;51:160-166.

28.

28. Berchuck A , Rodriquez G , Kinney RB , et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.

29.

29. Pisani AL , Barbuto DA , Chen D , Ramos L , Lagasse LD , Karlan BY . HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85:729-734.

30.

30. Clark GM , McGuire WL . Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:994-998.

31.

31. Ali IU , Campbell G , Lidereau R , Callahan R . Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Onco Res 1988;3:139-146.

32.

32. Tandon AK , Clark GM , Chamness GC , Ullrich A , McGuire Wl . HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128.

33.

33. Seshadri R , Firgaira FA , Horsfall DJ , McCaul K , Setlur V , Kitchen P . Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. Clin Oncol 1993;11:1936-1942.

34.

34. Ro JS , El-Naggar A , Ro JY , et al. c-erbB2 amplification in node-negative human breast cancer. Cancer Res 1989;49:6941-6944

35.

35. Van de Vijver MJ , Peterse JL , Mooi WJ , et al. neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.

36.

36. Parkes HC , Lillycrop K , Howell A , Craig RK . c-erbB2 mRNA expression in human breast tumors: Comparison with c-erbB2 DNA amplification and corrleation with prognosis. Br J Cancer 1990;61:39-45.

37.

37. Lacy MQ , Hartmann LC , Keeney GL , et al. c-erbB2-and p53 expression in fallopian tube carcinoma. Cancer 1995;75:2891-2896.

38.

38. Pinion SB , Kennedy JH , Miller RW , MacLean AB . Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of the cervix. Lancer 1991;337:819-820.

39.

39. Mitra AB , Murty VVVS , Pratap M , Sodhani P , Changanti RSK ERBB2 (HER-2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994;54:637-639.

40.

40. Jennings TS , Dottino PR , Mandeli JP , Segna RA , Kelliher K , Cohen CJ . Growth factor expression in normal peritoneum of patients with gynecologic carcinoma. Gynecol Oncol 1994;55:190-197.

41.

41. Zabrecky JR , Lam T , McKenzie SJ , Carney W . The extracellular domian of p185 neu is released from the surface of human breast carcinoma cell, SK-BR-3. J Biol Chem 1991;266:1716-1720.

42.

42. Langton BC , Crenshaw MC , Chao LA , Stuart SG , Akita RW , Jackson JE . An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB2-(HEr-2/neu) oncogene. Cancer Res 1991;51:2593-2598.

43.

43. Carney WP , Hamer PJ , Petit D , et al. Detection and quantitation of the human neu oncoprotein. J Tumor Market Oncol 1991;6:53-72.

44.

44. McKenzie SJ , Desombre KA , Bast BS , et al. Serum levels of HER-2/neu (c-erbB-2) correlated with overexpression of p185neu in human overian cancer. Cancer 1993;71:3942-3946.

45.

45. Meden H , Marx D , Fattahi A , et al. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J. Cancer Res Clin Oncol 1994;120:378-381.

46.

46. Cane P , Azen C , Lope zE , Platt LD , Karlan BY . Tumor marker trends in asymptomatic women at risk for ovarian cancer: Relevance for ovarian cancer screening. Gynecol Oncol 1995;57:240-245.

47.

47. Press MF , Cordon-Cardo C , Slamon DJ . Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-962.

48.

48. Niehans GA , Singleton TP , Dykoski D , Kiang DT . Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85:1230-1235.

49.

49. Carter P , Presta L , Gorman CM , et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4295-4299.

50.

50. Townsend A , Bodmer H . Antigen recognition by class I-restricted lymphocytes. Annu Rev Immunol 1989;7:601-624.

51.

51. People GE , Goedegebuure PS , Smith R , Linehan DC , Yoshino I , Eberlain TJ . Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. Proc Natl Acad Sci U S A 1995;92:432-436.

52.

52. Huang SK , Mayhew EM , Gilani S , Lasic DD , Martin FJ , Papahadjopoulos D . Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992;52:6774-6781.

53.

53. Park JW , Hong K , Carter P , et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995;92:1327-1331.

54.

54. Vaughn JP , Iglehart JD , Demirdji S , et al. Antisense DNA down-regulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Nat Acad Sci U S A 1995;92:8338-8342.